Assessment of kidney function in diabetic patients. Is there a role for new biomarkers NGAL, cystatin C and KIM-1?

Advances in Medical Sciences

Volumn 58, Issue 2, 2013, Pages 353-361

  Matys, U ^a   Bachorzewska Gajewska, H ^a   Malyszko, J ^a   Dobrzycki, S ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cystatin C; Diabetes; eGFR; KIM 1; NGAL

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CONTRAST MEDIUM; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KIDNEY INJURY MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; ERYTHROCYTE COUNT; ESTIMATED GLOMERULUS FILTRATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; LEAN BODY WEIGHT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT;

ACUTE-PHASE PROTEINS; AGED; ANGINA, STABLE; BIOLOGICAL MARKERS; CORONARY DISEASE; CYSTATIN C; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; LIPOCALINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; ROC CURVE;

EID: 84896887274     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-012-0077-8     Document Type: Article

References (40)

1. World Health Organization. Noncommunicable Diseases Country Profiles 2011. WHO global report [Internet]. Geneva [updated 2011 Sep; cited 2011 Dec 10]. Available from: http://www.who.int/nmh/countries/pol-en.pdf.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
3. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93(12):1515-9. (Pubitemid 38749208)
4. Coles M, Diercks T, Muehlenweg B, Bartsch S, Zölzer V, Tschesche H, et al. The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol. 1999;289(1):139-57. (Pubitemid 29278370)
5. Devarajan P. Neutrophil gelatinase-associated lipocalin-an emerging troponin for kidney injury. Nephrol Dial Transplant. 2008;23(12):3737-43.
6. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Poniatowski B, Pawlak K, Dobrzycki S. NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol. 2008;127(2):290-1. (Pubitemid 351795614)
7. Tuladhar SM, Püntmann VO, Soni M, Punjabi PP, Bogle RG. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharmacol. 2009;53:261-6.
8. Bennett, M, Dent, CL, Ma, Q, Dastrala S, Grenier F, Workman R, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008; 3:665-673.
9. Xin C, Yulong X, Yu C, Changchun C, Feng Z, Xinwei M. Urine neutrophil gelatinase-associated lipocalin and interleukin-18 predict acute kidney injury after cardiac surgery. Ren Fail. 2008;30:904-13.
10. Liangos O, Tighiouart H, Perianayagam MC, Kolyada A, Han WK, Wald R, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers. 2009;14:423-31.
11. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M. Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res. 2008;31(4):255-8.
12. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N, et al. Urinary neutrophil gelatinaseassociated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant. 2008;23(1):414-6. (Pubitemid 351767366)
13. Chew JS, Saleem M, Florkowski CM, George PM. Cystatin C-a paradigm of evidence based laboratory medicine. Clin Biochem Rev. 2008;29(2):47-62.
14. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29-34. (Pubitemid 30432560)
15. Felicio ML, Andrade RR, Castiglia YM, Silva MA, Vianna PT, Martins AS. Cystatin C and glomerular filtration rate in the cardiac surgery with cardiopulmonary bypass. Rev Bras Cir Cardiovasc. 2009;24:305-11.
16. Haase M, Bellomo R, Devarajan P, Ma Q, Bennett MR, Möckel M, Matalanis G, Dragun D, Haase-Fielitz A. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 2009;88:124-30.
17. Rickli H, Benou K, Ammann P, et al. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol. 2004; 61:98-102. (Pubitemid 38219904)
18. Herget-Rosenthal S, Marggraf G, Husing J, Göring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int.2004; 6:1115-22. (Pubitemid 39121017)
19. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 2008;73(7): 863-9. (Pubitemid 351398278)
20. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, et al. Urinary N-acetyl-beta-(D)- glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18(3):904-12. (Pubitemid 46434507)
21. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73(9):1008-16. (Pubitemid 351543898)
22. Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, et al. Effect of renin-angiotensin- aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis. 2009;53(1):16-25.
23. Matys U, Bachórzewska-Gajewska H, Małyszko J, Dobrzycki S. Ocena funkcji nerek u pacjentow z cukrzyca kierowanych na zabiegi przezskornych interwencji wiencowych [Evaluation of kidney function in diabetic patients undergoing percutaneous coronary interventions] Post Nauk Med. 2013;26(3):186-193. Polish.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
25. Lim WH, Lim EM, McDonald S. Lean body massadjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine. Nephrology. 2006;11(3):250-6. (Pubitemid 43829447)
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal disease Study Group. Ann Intern Med. 1999;130(6): 461-70. (Pubitemid 29135798)
27. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
28. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108(22):2769-75. (Pubitemid 37498979)
29. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18):1477-82. (Pubitemid 28228207)
30. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534-43. (Pubitemid 37169339)
31. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res. 2009;32(2):91-8.
32. Bolignano D, Coppolino G, Lacquaniti A, Nicocia G, Buemi M. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res. 2008;31(4):274-9.
33. Borges RL, Hirota AH, Quinto BM, Ribeiro AB, Zanella MT, Batista MC. Is Cystatin C a Useful Marker in the Detection of Diabetic Kidney Disease? Nephron Clin Pract 2010;114(2): c127-34.
34. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol. 2005;16(5):1404-12. (Pubitemid 41716524)
35. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145(4):237-46. (Pubitemid 46768607)
36. Parikh NI, Hwang SJ, Yang Q, Larson MG, Guo CY, Robins SJ, et al. Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol. 2008;102(9): 1194-8.
37. Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol. 2009;32(11):644-8.
38. Bonventre JV. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant. 2009;24(11):3265-8.
39. Waanders F, van Timmeren MM, Stegeman CA, Bakker SJ, van Goor H. Kidney injury molecule-1 in renal disease. J Pathol. 2010;220(1):7-16.
40. Perico N, Cattaneo D, Remuzzi G. Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. Am J Kidney Dis. 2009;53(1): 1-4.